摘要
目的:观察盐酸曲美他嗪片联合酒石酸美托洛尔缓释片治疗冠状动脉粥样硬化性心脏病(冠心病)心绞痛患者的效果。方法:选取2019年1月至2022年12月明溪县总医院收治的120例冠心病心绞痛患者进行前瞻性研究,按随机数字表法将其分为对照组和观察组各60例。对照组口服琥珀酸美托洛尔缓释片治疗,观察组在对照组基础上联合盐酸曲美他嗪片治疗,连续治疗14 d后,比较两组临床疗效,治疗前后超声心功能指标[左心室射血分数(LVEF)、每搏输出量(SV)、心输出量]、心率、心肌酶谱指标[肌酸激酶(CK)、α-羟丁酸脱氢酶(α-HBDH)、肌酸激酶同工酶(CK-MB)]水平,心绞痛发作频率、持续时间,以及不良反应发生率。结果:观察组治疗总有效率为95.00%(57/60),高于对照组的80.00%(48/60),差异有统计学意义(P<0.05);治疗后,观察组LVEF、心输出量、SV水平均高于对照组,心绞痛发作频率及血清CK、CK-MB、α-HBDH水平均低于对照组,心绞痛发作持续时间短于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:盐酸曲美他嗪片联合酒石酸美托洛尔缓释片治疗冠心病心绞痛患者可提高临床疗效,改善患者心排血量和心肌酶谱指标水平,降低心绞痛发作频率,缩短心绞痛发作持续时间,效果优于单用酒石酸美托洛尔缓释片治疗。
Objective:To observe effects of Trimetazidine hydrochloride tablets combined with Metoprolol tartrate sustained-release tablets in treatment of patients with coronary heart disease and angina pectoris.Methods:A prospective study was conducted on 120 patients with coronary heart disease and angina pectoris admitted to the Mingxi county general hospital from January 2019 to December 2022.They were divided into control group and observation group according to the random number table method,60 cases in each group.The control group was treated with Metoprolol succinate sustained-release tablets,while the observation group was treated with Trimetazidine hydrochloride tablets on the basis of that of the control group.After 14 days of continuous treatment,the clinical efficacy,the ultrasonic cardiac function index levels[left ventricular ejection fraction(LVEF),stroke volume(SV),cardiac output],the heart rate,the myocardial enzyme index levels[creatine kinase(CK),α-hydroxybutyrate dehydrogenase(α-HBDH),creatine kinase isoenzyme(CK-MB)]before and after the treatment,the frequency and duration of angina pectoris,and the incidence of adverse reactions were compared between the two groups.Results:The effective rate of treatment in the observation group was 95.00%(57/60),which was higher than 80.00%(48/60)in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of LVEF,cardiac output and SV in the observation group were higher than those in the control group,the frequency of angina pectoris and the levels of serum CK,CK-MB andα-HBDH were lower than those in the control group,and the duration of angina pectoris was shorter than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Trimetazidine hydrochloride tablets combined with Metoprolol tartrate sustained-release tablets in the treatment of the patients with angina pectoris and coronary heart disease can improve the clinical efficacy,improve the cardiac output and the myocardial enzyme levels,reduce the frequency of angina pectoris and shorten the duration of angina pectoris.Moreover,it is superior to single Metoprolol tartrate sustained-release tablets treatment.
作者
李爱珍
肖志强
LI Aizhen;XIAO Zhiqiang(Department of Internal Medicine of Mingxi County General Hospital,Sanming 365200 Fujian,China;Department of Cardiology of Sanming First Hospital,Sanming 365200 Fujian,China)
出处
《中国民康医学》
2023年第17期40-42,46,共4页
Medical Journal of Chinese People’s Health
关键词
冠心病
心绞痛
美托洛尔
曲美他嗪
心功能
心肌酶谱
Coronary heart disease
Angina pectoris
Metoprolol
Trimetazidine
Cardiac function
Myocardial enzyme
